Bioventus (BVS) Competitors

Bioventus (NYSE:BVS) and Envista (NYSE:NVST) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership.

Does the media refer more to BVS or NVST?

In the previous week, Envista had 11 more articles in the media than Bioventus. MarketBeat recorded 16 mentions for Envista and 5 mentions for Bioventus. Bioventus' average media sentiment score of 1.12 beat Envista's score of 0.26 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Envista	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in BVS or NVST?

Envista received 3 more outperform votes than Bioventus when rated by MarketBeat users. However, 63.27% of users gave Bioventus an outperform vote while only 33.01% of users gave Envista an outperform vote.

Company	Underperform	Outperform
Bioventus	Outperform Votes 31 63.27%	Underperform Votes 18 36.73%
Envista	Outperform Votes 34 33.01%	Underperform Votes 69 66.99%

Which has more risk and volatility, BVS or NVST?

Bioventus has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Envista has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Which has preferable valuation and earnings, BVS or NVST?

Bioventus has higher earnings, but lower revenue than Envista. Bioventus is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$573.28M	1.11	-$156.23M	-$0.51	-15.18
Envista	$2.51B	1.04	-$1.12B	-$6.49	-2.33

Do analysts prefer BVS or NVST?

Bioventus presently has a consensus price target of $15.00, indicating a potential upside of 93.80%. Envista has a consensus price target of $19.96, indicating a potential upside of 31.91%. Given Bioventus' stronger consensus rating and higher probable upside, equities analysts plainly believe Bioventus is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Envista	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07

Is BVS or NVST more profitable?

Bioventus has a net margin of -7.11% compared to Envista's net margin of -44.56%. Bioventus' return on equity of 15.61% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	-7.11%	15.61%	4.01%
Envista	-44.56%	3.86%	2.21%

Do institutionals & insiders have more ownership in BVS or NVST?

62.9% of Bioventus shares are held by institutional investors. 32.9% of Bioventus shares are held by insiders. Comparatively, 1.3% of Envista shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Bioventus beats Envista on 12 of the 18 factors compared between the two stocks.